AARD

Aardvark Therapeutics

AARD

Market cap $311M

14.27 USD

-0.24

1.65%

At close Updated Jan 9, 4:00 PM EST

Pre-market

After hours

14.30

+0.03

0.21%

1 day

-1.65%

5 days

5.86%

1 month

4.24%

3 months

-13.98%

6 months

12.1%

Year to date

8.19%

1 year

-0.28%

5 years

-0.28%

10 years

-0.28%

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 33

Healthcare Biotechnology